Granules India Limited (GRANULES) Fair Value & Analysis

Healthcare · IN · Market cap ₹205B

A solid business, screening 11% undervalued on our models.

What matters now

• A fairly wide model range (₹491.56 to ₹1,189) leaves room in how you read the outcome.
• Our model range runs from ₹491.56 (bear) to ₹1,189 (bull), base ₹950.89. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 52/100 (solid quality) with high evidence: the data supports the verdict.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹230.36 – ₹903.25 · fair‑value band ₹491.56 – ₹1,189 · the ₹858.40 price screens below the ₹950.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Granules India Limited (GRANULES) currently trades at ₹858.40, while our model-based Fair Value estimate is ₹950.89, implying the stock looks roughly 10.8% undervalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Granules India Limited generated revenue of ₹53.7B at a net margin of 11.1%. Revenue grew 22.8% year over year. It earns a return on equity of 13.5%. Net debt stands at ₹5.6B. Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹491.56 (bear case) to ₹1,189 (bull case); at ₹858.40, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 98% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 11%, GRANULES screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹601.33) versus Dividend Discount (₹25.27). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products.

Full company description

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Granules India Limited reported revenue of ₹53.7B in FY2026 versus ₹37.6B in FY2022, a compound +9.3%/yr. Reported net income was ₹6.0B in FY2026, compounding +9.6%/yr from FY2022.

Watch GRANULES: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 622 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.